Ketone supplementation

Phase 1Small molecule

VVanderbilt University Medical Center

Ketone supplementation is one of 26 small molecule programs targeting Delirium. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DeliriumActive, not recruiting

DeliriumPhase 1

Active, not recruiting

Competition

Competitive Landscape

167 competitors in Delirium

#DrugCompanyPhaseTrials

Luvox

SSolvay Pharmaceuticals

Phase 3

1 2

Rozerem

Takeda

Preclinical

6 3

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 4

Anerem

AAcacia Pharma Ltd

Preclinical

7 5

Spravato

WWim Janssens

Preclinical

4 6

Raldesy

PPragma

Preclinical

3 7

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

2 8

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 9

Methylthioninium Chloride

PProvepharm SAS

Preclinical

1 10

Levophed

GGeneral Hospital of Ningxia Medical University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Delirium

NCT07364162

Clinical

Trials by Indication[1]

Caloric Restriction1 trial

Effects of Ketones on Muscle Wasting During Caloric Restriction in Lean Females

Completed·KKU Leuven·N/A·NCT04744142·44 enrolled

Delirium1 trial

Exogenous Ketone Supplementation in ICU Delirium

Not yet recruiting·VVanderbilt University Medical Center·Phase 1·NCT07364162·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ketone supplementation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ketone supplementation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ketone supplementation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanderbilt University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VVanderbilt University Medical Center

Ketone supplementation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Caloric Restriction1 trial

Delirium1 trial

References

Drug Info

Quick Facts

Related News